Choon-Ok Kim

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3505794/publications.pdf

Version: 2024-02-01

		1039880	940416
35	297	9	16
papers	citations	h-index	g-index
35	35	35	550
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Verapamil decreases the glucoseâ€lowering effect of metformin in healthy volunteers. British Journal of Clinical Pharmacology, 2014, 78, 1426-1432.	1.1	62
2	Impact of ABCC2, ABCC2 and SLCO1B1 Polymorphisms on the Pharmacokinetics of Pitavastatin in Humans. Drug Metabolism and Pharmacokinetics, 2013, 28, 196-202.	1.1	36
3	Functional characterization of MATE2-K genetic variants and their effects on metformin pharmacokinetics. Pharmacogenetics and Genomics, 2013, 23, 365-373.	0.7	24
4	Is abdominal obesity associated with the 2009 influenza A (H1N1) pandemic in Korean schoolâ€aged children?. Influenza and Other Respiratory Viruses, 2012, 6, 313-317.	1.5	23
5	Relationship Between Earlobe Crease and Brachial-ankle Pulse Wave Velocity in Non-hypertensive, Non-diabetic Adults in Korea. Epidemiology and Health, 2009, 31, e2009002.	0.8	13
6	Pharmacokinetic Interaction Between Amlodipine and Lobeglitazone, a Novel Peroxisome Proliferator–activated Receptor-γ Agonist, in Healthy Subjects. Clinical Therapeutics, 2015, 37, 1999-2006.e1.	1.1	12
7	Comparison of Pharmacokinetics and Safety of a Fixed-dose Combination of Rosuvastatin and Ezetimibe Versus Separate Tablets in Healthy Subjects. Clinical Therapeutics, 2017, 39, 1799-1810.	1.1	12
8	Association between Daily Sunlight Exposure and Fractures in Older Korean Adults with Osteoporosis: A Nationwide Population-Based Cross-Sectional Study. Yonsei Medical Journal, 2021, 62, 593.	0.9	11
9	Association Between 10-Year Fracture Probability and Nonalcoholic Fatty Liver Disease With or Without Sarcopenia in Korean Men: A Nationwide Population-Based Cross-Sectional Study. Frontiers in Endocrinology, 2021, 12, 599339.	1.5	11
10	Clinical Predictors of Novel Influenza A (H1N1) Infection in Korea. Yonsei Medical Journal, 2010, 51, 895.	0.9	10
11	Influence of Hepatic Dysfunction on the Pharmacokinetics and Safety of Fimasartan. Journal of Cardiovascular Pharmacology, 2013, 62, 524-529.	0.8	9
12	Pharmacokinetic interactions between glimepiride and rosuvastatin in healthy Korean subjects: does the SLCO1B1 or CYP2C9 genetic polymorphism affect these drug interactions?. Drug Design, Development and Therapy, 2017, Volume11, 503-512.	2.0	9
13	The safety, pharmacodynamics, and pharmacokinetics of immediate-release formulation containing esomeprazole 20 mg/sodium bicarbonate 800 mg in healthy adult male. Drug Design, Development and Therapy, 2019, Volume 13, 3151-3159.	2.0	9
14	Effects of Gelidium elegans on Weight and Fat Mass Reduction and Obesity Biomarkers in Overweight or Obese Adults: A Randomized Double-Blinded Study. Nutrients, 2019, 11, 1513.	1.7	8
15	Pharmacokinetic drug interaction between atorvastatin and ezetimibe in healthy Korean volunteers. Translational and Clinical Pharmacology, 2017, 25, 202.	0.3	6
16	Effect of Ketoconazole on Lobeglitazone Pharmacokinetics in Korean Volunteers. Clinical Therapeutics, 2014, 36, 1064-1071.	1.1	5
17	Firstâ€inâ€human study with new recombinant agalsidase beta (ISU303) in healthy subjects. Journal of Clinical Pharmacology, 2014, 54, 675-681.	1.0	4
18	Prevalence of Gallbladder Polyp in Adults in Korea. Korean Journal of Family Medicine, 2009, 30, 39.	0.4	4

#	Article	IF	Citations
19	Evaluation of pharmacokinetic interactions between amoxicillin, clarithromycin, and the potassium-competitive acid blocker YH4808 in healthy subjects. Translational and Clinical Pharmacology, 2020, 28, 55.	0.3	4
20	Pharmacodynamic evaluation of YH4808 for Helicobacter pylori eradication in healthy subjects. Translational and Clinical Pharmacology, 2020, 28, 136.	0.3	4
21	Coagulant Effect and Tolerability of Yeast-Produced Recombinant Batroxobin in Healthy Adult Subjects. Clinical Drug Investigation, 2018, 38, 829-835.	1.1	3
22	Pharmacokinetics, pharmacodynamics and safety of CKD-519, a CETP inhibitor, in healthy subjects. Drug Design, Development and Therapy, 2016, Volume 10, 3763-3770.	2.0	2
23	Comparison of pharmacokinetics and safety of fixed-dose combination of SKI306X and aceclofenac versus separate tablets in healthy subjects. Translational and Clinical Pharmacology, 2017, 25, 196.	0.3	2
24	Comparison of biosimilar filgrastim with a reference product: pharmacokinetics, pharmacodynamics, and safety profiles in healthy volunteers. Drug Design, Development and Therapy, 2018, Volume 12, 2381-2387.	2.0	2
25	Pharmacokinetics and safety of evogliptin in hepatically impaired patients. British Journal of Clinical Pharmacology, 2020, 87, 2757-2766.	1.1	2
26	Association between daily sunlight exposure duration and diabetic retinopathy in Korean adults with diabetes: A nationwide population-based cross-sectional study. PLoS ONE, 2020, 15, e0237149.	1.1	2
27	Population Pharmacokinetics of Primaquine in the Korean Population. Pharmaceutics, 2021, 13, 652.	2.0	2
28	Bioequivalence and Dose Proportionality of Olmesartan Medoxomil Formulations. Journal of the Korean Society for Clinical Pharmacology and Therapeutics, 2012, 20, 145.	0.1	1
29	Effects of JOINS® on the pharmacokinetic profiles of aceclofenac in healthy Korean volunteers: an open-label, multiple-dose, one sequence, two-period study. Translational and Clinical Pharmacology, 2016, 24, 169.	0.3	1
30	Decreased potency of fimasartan in liver cirrhosis was quantified using mixed-effects analysis. Translational and Clinical Pharmacology, 2017, 25, 43.	0.3	1
31	A comparison of the pharmacokinetic and pharmacodynamic properties of nitroglycerin according to the composition of the administration set. Medicine (United States), 2018, 97, e9829.	0.4	1
32	Comparison of the pharmacokinetics and pharmacodynamics of YH4808 in healthy subjects for defining an appropriate dosing regimen. Translational and Clinical Pharmacology, 2021, 29, 150.	0.3	1
33	Effects of Hepatic Impairment on the Pharmacokinetic Profile and Safety of Lobeglitazone. Clinical Pharmacology in Drug Development, 2022, 11, 576-584.	0.8	1
34	A Population Pharmacokinetic and Pharmacodynamic Model of CKD-519. Pharmaceutics, 2020, 12, 573.	2.0	0
35	A Case Report of Sepsis by Extended-Spectrum β-Lactamase Producing Escherichia Coli. Korean Journal of Family Medicine, 2010, 31, 384.	0.4	0